Literature DB >> 29233929

Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle-Related Transcription and Attenuated Androgen Response.

Aaron M Horning1, Yao Wang1, Che-Kuang Lin1, Anna D Louie1, Rohit R Jadhav1, Chia-Nung Hung1,2, Chiou-Miin Wang1, Chun-Lin Lin1, Nameer B Kirma1, Michael A Liss3, Addanki P Kumar3, LuZhe Sun4, Zhijie Liu1, Wei-Ting Chao2, Qianben Wang5, Victor X Jin1, Chun-Liang Chen6, Tim H-M Huang6.   

Abstract

Increasing evidence suggests the presence of minor cell subpopulations in prostate cancer that are androgen independent and poised for selection as dominant clones after androgen deprivation therapy. In this study, we investigated this phenomenon by stratifying cell subpopulations based on transcriptome profiling of 144 single LNCaP prostate cancer cells treated or untreated with androgen after cell-cycle synchronization. Model-based clustering of 397 differentially expressed genes identified eight potential subpopulations of LNCaP cells, revealing a previously unappreciable level of cellular heterogeneity to androgen stimulation. One subpopulation displayed stem-like features with a slower cell doubling rate, increased sphere formation capability, and resistance to G2-M arrest induced by a mitosis inhibitor. Advanced growth of this subpopulation was associated with enhanced expression of 10 cell-cycle-related genes (CCNB2, DLGAP5, CENPF, CENPE, MKI67, PTTG1, CDC20, PLK1, HMMR, and CCNB1) and decreased dependence upon androgen receptor signaling. In silico analysis of RNA-seq data from The Cancer Genome Atlas further demonstrated that concordant upregulation of these genes was linked to recurrent prostate cancers. Analysis of receiver operating characteristic curves implicates aberrant expression of these genes and could be useful for early identification of tumors that subsequently develop biochemical recurrence. Moreover, this single-cell approach provides a better understanding of how prostate cancer cells respond heterogeneously to androgen deprivation therapies and reveals characteristics of subpopulations resistant to this treatment.Significance: Illustrating the challenge in treating cancers with targeted drugs, which by selecting for drug resistance can drive metastatic progression, this study characterized the plasticity and heterogeneity of prostate cancer cells with regard to androgen dependence, defining the character or minor subpopulations of androgen-independent cells that are poised for clonal selection after androgen-deprivation therapy. Cancer Res; 78(4); 853-64. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29233929      PMCID: PMC5983359          DOI: 10.1158/0008-5472.CAN-17-1924

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

1.  The program of androgen-responsive genes in neoplastic prostate epithelium.

Authors:  Peter S Nelson; Nigel Clegg; Hugh Arnold; Camari Ferguson; Michael Bonham; James White; Leroy Hood; Biaoyang Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-16       Impact factor: 11.205

2.  Assignment of two human cell cycle genes, CDC25C and CCNB1, to 5q31 and 5q12, respectively.

Authors:  H Sartor; F Ehlert; K H Grzeschik; R Müller; S Adolph
Journal:  Genomics       Date:  1992-07       Impact factor: 5.736

3.  Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

Authors:  Jack Cuzick; Gregory P Swanson; Gabrielle Fisher; Arthur R Brothman; Daniel M Berney; Julia E Reid; David Mesher; V O Speights; Elzbieta Stankiewicz; Christopher S Foster; Henrik Møller; Peter Scardino; Jorja D Warren; Jimmy Park; Adib Younus; Darl D Flake; Susanne Wagner; Alexander Gutin; Jerry S Lanchbury; Steven Stone
Journal:  Lancet Oncol       Date:  2011-03       Impact factor: 41.316

4.  Synchronization of HeLa cells.

Authors:  Hoi Tang Ma; Randy Y C Poon
Journal:  Methods Mol Biol       Date:  2011

Review 5.  The biology of hormone refractory prostate cancer. Why does it develop?

Authors:  J T Isaacs
Journal:  Urol Clin North Am       Date:  1999-05       Impact factor: 2.241

6.  Cell cycle-regulated expression, phosphorylation, and degradation of p55Cdc. A mammalian homolog of CDC20/Fizzy/slp1.

Authors:  J Weinstein
Journal:  J Biol Chem       Date:  1997-11-07       Impact factor: 5.157

7.  A novel mammalian protein, p55CDC, present in dividing cells is associated with protein kinase activity and has homology to the Saccharomyces cerevisiae cell division cycle proteins Cdc20 and Cdc4.

Authors:  J Weinstein; F W Jacobsen; J Hsu-Chen; T Wu; L G Baum
Journal:  Mol Cell Biol       Date:  1994-05       Impact factor: 4.272

8.  Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort.

Authors:  J Cuzick; D M Berney; G Fisher; D Mesher; H Møller; J E Reid; M Perry; J Park; A Younus; A Gutin; C S Foster; P Scardino; J S Lanchbury; S Stone
Journal:  Br J Cancer       Date:  2012-02-23       Impact factor: 7.640

9.  Bayesian approach to single-cell differential expression analysis.

Authors:  Peter V Kharchenko; Lev Silberstein; David T Scadden
Journal:  Nat Methods       Date:  2014-05-18       Impact factor: 28.547

10.  HTSeq--a Python framework to work with high-throughput sequencing data.

Authors:  Simon Anders; Paul Theodor Pyl; Wolfgang Huber
Journal:  Bioinformatics       Date:  2014-09-25       Impact factor: 6.937

View more
  38 in total

Review 1.  Tumor Dormancy and Slow-Cycling Cancer Cells.

Authors:  John E Davis; Jason Kirk; Yibing Ji; Dean G Tang
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

2.  Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas.

Authors:  Reuben Moncada; Dalia Barkley; Florian Wagner; Marta Chiodin; Joseph C Devlin; Maayan Baron; Cristina H Hajdu; Diane M Simeone; Itai Yanai
Journal:  Nat Biotechnol       Date:  2020-01-13       Impact factor: 54.908

3.  Epigenetic analysis identifies factors driving racial disparity in prostate cancer.

Authors:  Richa Rai; Shalini S Yadav; Heng Pan; Irtaza Khan; James O'Connor; Mohammed Alshalalfa; Elai Davicioni; Emanuela Taioli; Olivier Elemento; Ashutosh K Tewari; Kamlesh K Yadav
Journal:  Cancer Rep (Hoboken)       Date:  2018-12-13

Review 4.  Engineering Multidimensional Evolutionary Forces to Combat Cancer.

Authors:  Caroline E McCoach; Trever G Bivona
Journal:  Cancer Discov       Date:  2019-04-16       Impact factor: 39.397

5.  The Therapeutic Effect of iMSC-Derived Small Extracellular Vesicles on Tendinopathy Related Pain Through Alleviating Inflammation: An in vivo and in vitro Study.

Authors:  Zhaochen Zhu; Renzhi Gao; Teng Ye; Kai Feng; Juntao Zhang; Yu Chen; Zongping Xie; Yang Wang
Journal:  J Inflamm Res       Date:  2022-03-01

6.  The Prognostic Assessment of CDC20 in Patients with Renal Clear Cell Carcinoma and Its Relationship with Body Immunity.

Authors:  Jiaqi Shi; Yinhao Chen; Xiameng Gu; Xuerong Wang; Jing Liu; Xiaolan Chen
Journal:  Contrast Media Mol Imaging       Date:  2022-06-08       Impact factor: 3.009

7.  Single-cell RNA-Seq of follicular lymphoma reveals malignant B-cell types and coexpression of T-cell immune checkpoints.

Authors:  Noemi Andor; Erin F Simonds; Debra K Czerwinski; Jiamin Chen; Susan M Grimes; Christina Wood-Bouwens; Grace X Y Zheng; Matthew A Kubit; Stephanie Greer; William A Weiss; Ronald Levy; Hanlee P Ji
Journal:  Blood       Date:  2018-12-27       Impact factor: 22.113

8.  CDC20 and PTTG1 are Important Biomarkers and Potential Therapeutic Targets for Metastatic Prostate Cancer.

Authors:  Liang Dai; Zi-Xuan Song; Da-Peng Wei; Ji-Dong Zhang; Jun-Qiang Liang; Bai-Bing Wang; Wang-Teng Ma; Li-Ying Li; Yin-Lu Dang; Liang Zhao; Li-Min Zhang; Yu-Ming Zhao
Journal:  Adv Ther       Date:  2021-04-21       Impact factor: 3.845

9.  High copy number variations, particular transcription factors, and low immunity contribute to the stemness of prostate cancer cells.

Authors:  Zao Dai; Ping Liu
Journal:  J Transl Med       Date:  2021-05-13       Impact factor: 5.531

10.  Centromere protein F (CENPF), a microtubule binding protein, modulates cancer metabolism by regulating pyruvate kinase M2 phosphorylation signaling.

Authors:  Muhammad Shahid; Min Young Lee; Honit Piplani; Allen M Andres; Bo Zhou; Austin Yeon; Minjung Kim; Hyung L Kim; Jayoung Kim
Journal:  Cell Cycle       Date:  2018-12-17       Impact factor: 5.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.